Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colistin loading dose in pediatric severe gram-negative infections
IRCT20170614034532N2Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jul 2018
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of colistin and meropenem in bloodstream infection (BSI) and ventilator-associated pneumonia (VAP) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Clinical response, Microbial clearance and 3 more. Started Jul 2018; status: completed.
02
Drugs
colistinmeropenem
03
Conditions
bloodstream infection (BSI)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on IRCT20170614034532N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170614034532N2.